semaglutide and liver disease 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Fatty liver disease quietly raises

The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets

Oral Supplements: Capsules and powders often face challenges related to poor bioavailability due to the digestive process, which can degrade glutathione before it reaches the bloodstream

Mobile users can scroll to the right to access all the data

References Aon, M